ReviewSN comprehensive clinical medicine2020
Efficacy of Plasmapheresis and Immunoglobulin Replacement Therapy (IVIG) on Patients with COVID-19.
Review in SN comprehensive clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies.European journal of pharmacology · 2021Pooled it
- A systematic review of pregnant women with COVID-19 and their neonates.Archives of gynecology and obstetrics · 2021Pooled it
- Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review.Bioorganic chemistry · 2021Pooled it
- Therapeutic Plasma Exchange in Intensive Care Units-A 5-Year Multicenter Retrospective Study.Life (Basel, Switzerland) · 2025Article
- Research progress of post-acute sequelae after SARS-CoV-2 infection.Cell death & disease · 2024Review
- Peripheral immune landscape for hypercytokinemia in myasthenic crisis utilizing single-cell transcriptomics.Journal of translational medicine · 2023Article
- Diagnosis of the right atrial myxoma after treatment of COVID-19: A case report.Clinical case reports · 2023Article
- Efficacy and safety of Tocilizumab, plasmapheresis and their combination in severe COVID-19: A randomized clinical trial.International immunopharmacology · 2023Review
- The autonomic aspects of the post-COVID19 syndrome.Autoimmunity reviews · 2022Review
- Review
- The outcome of using intravenous immunoglobulin (IVIG) in critically ill COVID-19 patients': a retrospective, multi-centric cohort study.European journal of medical research · 2022Article
- Computed tomography scan in COVID-19: a systematic review and meta-analysis.Polish journal of radiology · 2022Review
- Therapeutic Plasma Exchanges in Combination with High-Dose Steroid-Induced Immunosuppression as an Ultima Ratio Therapy in Severe Coronavirus Disease 2019 (COVID-19): A Case-Series Report.Journal of inflammation research · 2022Article
- Gastrointestinal manifestations in COVID-19.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2021Review
- Potential therapeutic approach of intravenous immunoglobulin against COVID-19.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2021Review
- Recent advances in antibody-based immunotherapy strategies for COVID-19.Journal of cellular biochemistry · 2021Review
- Altered immunoemotional regulatory system in COVID-19: From the origins to opportunities.Journal of neuroimmunology · 2021Review
- Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment.Atherosclerosis · 2021Review
- The find of COVID-19 vaccine: Challenges and opportunities.Journal of infection and public health · 2021Review
- Successful treatment of plasmapheresis followed by interferon beta-1a in a child with severe COVID-19.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the rapidly evolving outbreak of COVID-19, several empirical therapeutic options have been recommended including the use of antivirals, steroids, and vaccines. According to recent observations about different modalities in treatment of patients infected with COVID-19, plasmapheresis and intravenous immunoglobulin (IVIg) have been reported to be an effective empirical therapeutic option to control the infection. In this review, we aimed to provide an overview on the possible application of plasmapheresis and intravenous immunoglobulin in patients with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.